
    
      Subjects will be randomized to receive lenabasum 20 mg twice per day, lenabasum 5 mg twice
      per day, or placebo twice per day in a 2:1:2 ratio. The primary efficacy outcome at Week 52
      will be Total Improvement Score (TIS), which is a weighted composite measure of improvement
      from baseline in six endpoints: Physician Global Assessment of Disease Activity, Physician
      Assessment of Extramuscular Disease Activity, Patient Global Assessment of Disease Activity,
      Health Assessment Questionnaire (patient-reported disability), Manual Muscle Testing (MMT),
      and muscle enzymes.
    
  